Genomes and Genes
Affiliation: Duke University Medical Center
- A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assaysJeffrey R Currier
The US Military HIV Research Program, Suite 200, 13 Taft Court, Rockville, MD 20851, USA
J Immunol Methods 260:157-72. 2002..The size, shape and appearance of the spots produced using this peptide panel provided a standard for the establishment of acceptance criteria of spots for the evaluation of ELISPOT plates using an automated reader system...
- Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infectionGuido Ferrari
Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
PLoS Pathog 7:e1001273. 2011....
- High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responsesJustin Pollara
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
Cytometry A 79:603-12. 2011....
- Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responsesJustin Pollara
Department of Surgery, Duke University Medical Center, P O Box 2926, Durham, NC 27710, USA
Curr HIV Res 11:378-87. 2013..Here we discuss the HIV-1 envelope epitopes targeted by ADCC antibodies in the context of the potential protective capacities of ADCC. ..
- An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serumGuido Ferrari
Duke University Medical Center, Department of Surgery, P O Box 2926, Durham, NC 27710, USA
J Virol 85:7029-36. 2011..These data demonstrate that the epitope defined by MAb A32 is a major target on gp120 for plasma ADCC activity...
- HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected EthiopiansGuido Ferrari
Duke University, Durham, NC, USA
Hum Immunol 65:648-59. 2004..These data represent the first report of correlating HLA phenotype and HIV-specific cell-mediated immune responses among infected Ethiopians and may be useful in designing cytotoxic T lymphocyte-inducing vaccines for this part of Africa...
- Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 alleleGuido Ferrari
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Immunol 173:2126-33. 2004....
- Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordanceSusan S Kaplan
Department of Medicine, Duke University Medical Center, Durham, NC 22710, USA
AIDS Res Hum Retroviruses 21:13-6. 2005..Thus, CD4(+)/VL discordance can be maintained for periods exceeding 5 years in some patients receiving PI-based HAART without significant evolution of HIV resistance...
- Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras
Duke Human Vaccine Institute, and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 110:9019-24. 2013..We show that monomeric Env-specific IgA, as part of postvaccination polyclonal antibody response, may modulate vaccine-induced immunity by diminishing ADCC effector function...
- Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccineesPinghuang Liu
Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
J Virol 87:7828-36. 2013..Although capture of infectious HIV-1 correlated with other humoral immune responses, the extent of variation between these humoral responses and virion capture indicates that virion capture antibodies occupy unique immunological space. ..
- Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2Hua Xin Liao
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
Immunity 38:176-86. 2013..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
- Acute HIV-1 infection in the Southeastern United States: a cohort studyMehri S McKellar
Duke University, Durham, NC 27710, USA
AIDS Res Hum Retroviruses 29:121-8. 2013..Highlighting the challenges of diagnosing AHI, less than half of the patients were diagnosed at the first healthcare visit. Women made up a small proportion despite increasing numbers in our clinics...
- Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replicationStephanie A Freel
Department of Surgery, Duke University Human Vaccine Institute, Durham, North Carolina, USA
J Virol 86:6835-46. 2012....
- HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activitiesJustin Pollara
Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
J Virol 88:7715-26. 2014..This is a major step in understanding how these types of antibodies may have cooperatively contributed to reducing infection risk and should be considered in the context of prospective vaccine design...
- Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccinationStephanie A Freel
Duke University Human Vaccine Institute, Departments of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
J Virol 84:4998-5006. 2010..Our data define attributes of an antiviral CD8(+) T-cell response that may be optimized in the search for an efficacious HIV-1 vaccine...
- Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant VirusesM Anthony Moody
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA Electronic address
Cell Host Microbe 18:354-62. 2015....
- HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineagesM Anthony Moody
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
J Virol 86:7496-507. 2012..Improved vaccination strategies will be needed to drive persistent stimulation of antibody clonal lineages to induce affinity maturation that results in highly mutated HIV-1 Env-reactive antibodies...
- Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaquesM Anthony Moody
Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
J Virol 88:3329-39. 2014....
- Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyMattia Bonsignori
Duke University Medical Center, Durham, North Carolina, USA
J Virol 86:11521-32. 2012..The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbs...
- Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus functionGregory D Sempowski
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
J Clin Immunol 25:462-72. 2005....
- Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes
Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
N Engl J Med 366:1275-86. 2012..In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk...
- Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durabilityCynthia L Gay
aDepartment of Medicine, UNC Institute for Global Health and Infectious Diseases bDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill cDepartment of Medicine, Division of Infectious Diseases dDepartment of Surgery eDuke Human Vaccine Institute, Duke University, Durham fLaboratory Corporation of America, Burlington, North Carolina gDepartment of Clinical Medicine, University of San Diego, San Diego, California, USA
AIDS 30:2815-2822. 2016..Updated guidelines recommend immediate antiretroviral treatment (ART) during acute HIV infection (AHI), but efficacy data on regimens during AHI are limited...
- Progress in HIV-1 vaccine developmentBarton F Haynes
Duke Human Vaccine Institute, Durham, NC Department of Medicine, Duke University School of Medicine, Durham, NC Department of Immunology, Duke University School of Medicine, Durham, NC Electronic address
J Allergy Clin Immunol 134:3-10; quiz 11. 2014..This review summarizes what some of the scientific advances have been, what roadblocks still remain, and what the most promising approaches are for progress in design of successful HIV-1 vaccine candidates. ..
- Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milkGenevieve G A Fouda
Duke Human Vaccine Institute, Durham, North Carolina, USA
J Virol 87:6986-99. 2013..This study shows that systemic MVA prime followed by either intranasal or systemic protein boosts can elicit strong humoral responses in breast milk and may be a useful strategy to interrupt postnatal HIV-1 transmission...
- Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrumJames Friedman
Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States
PLoS ONE 7:e37648. 2012..Therefore, characterization of HIV-specific antibodies produced by B cells in milk could guide the development of vaccines that elicit protective mucosal antibody responses...
- CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infectionMarc A Frahm
Center for AIDS Research, Duke University Medical Center, Durham, NC 22710, USA
J Immunol 188:4289-96. 2012..Therefore, DP T cells represent a highly reactive cell population during acute HIV infection, which responds independently from the traditional T cell compartments...
- Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responsesGenevieve G Fouda
Duke University, Durham, North Carolina
J Infect Dis 211:508-17. 2015..Infant responses to vaccines can be impeded by maternal antibodies and immune system immaturity. It is therefore unclear whether human immunodeficiency virus type 1 (HIV-1) vaccination would elicit similar responses in adults and infants...
- Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates
Duke Human Vaccine Institute, Durham, NC 27710, USA
Sci Transl Med 6:228ra39. 2014..These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials. ..
- Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine designNancy Gasper-Smith
Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
J Virol 82:7700-10. 2008....
- Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studiesWes Rountree
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA Electronic address
J Immunol Methods 433:69-76. 2016..To determine significant lot-to-lot variations use the 3.3 dispersion limit for between and within experiment variability. ..
- Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1Justin Pollara
Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA
J Virol 89:9952-61. 2015..This finding supports further investigations into the mechanisms by which mucosal IgA reduces risk of HIV-1 transmission via breast milk and into immune interventions aimed at enhancing this response...
- HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodiesWilton B Williams
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA
Science 349:aab1253. 2015..Thus, HIV-1 Env DNA-rAd5 vaccine induced a dominant IM-polyreactive, non-neutralizing gp41-reactive Ab repertoire response that was associated with no vaccine efficacy. ..
- Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibitionTamika L Payne
Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
J Virol 88:9514-28. 2014..This coordinated response allows rapid and robust induction of mRNA messages that can enhance the CD8+ T cells' ability to inhibit virus upon antigen encounter...
- Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infectionGuido Ferrari
Department of Surgery, Duke University, Durham, North Carolina 27710, USA
Nat Rev Drug Discov 15:823-834. 2016..Here, we review these immunotherapies, which are designed with the goal of curing HIV-1 infection...
- Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus MacaquesDonatella Negri
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
Mol Ther 24:2021-2032. 2016..Our study demonstrates that an IDLV-Env-based vaccine induces functional, comprehensive, and durable immune responses in Rhesus macaques. These results support further evaluation of IDLV as a new HIV-1 vaccine delivery platform...
- Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virusRuijun Zhang
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA
Nat Commun 7:12131. 2016..Our results support the use of AGMs to model induction of functional gp120-specific antibodies by HIV vaccine strategies. ..
- Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramideS Moses Dennison
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
J Virol 88:9406-17. 2014..However, the MAb 17B itself did not block Env-Galcer binding, suggesting that the C1 antibody-induced gp120 conformational changes resulted in alteration in a Galcer binding site distant from the CD4i 17B MAb binding site...
- The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assayAna M Sanchez
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
J Immunol Methods 409:31-43. 2014....
- Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genomeHongshuo Song
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
Retrovirology 9:89. 2012....
- HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodiesGenevieve G Fouda
Duke Human Vaccine Institute, Duke University Medical Center, Box 103020, Durham, NC 27710, USA
J Virol 85:9555-67. 2011..These results suggest that plasma-derived IgG antibodies mediate the majority of the low-level HIV neutralization and ADCC activity in breast milk...
- Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapyCynthia Gay
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America
PLoS ONE 6:e19617. 2011..We studied subjects with AHI prospectively to develop better treatment and public health interventions...
- Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast MilkCody S Nelson
Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
J Virol 90:4951-65. 2016..Thus, maternal i.n./i.m. combined immunization is a novel strategy to enhance protective Env-specific IgA in milk, which is subsequently transferred to the infant via breastfeeding...
- Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programsAmbrosia Garcia
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
J Immunol Methods 409:99-106. 2014....
- The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cellsMARCELLA SARZOTTI-KELSOE
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA Department of Surgery, Duke University Medical Center, Durham, NC, USA Department of Immunology, Duke University Medical Center, Durham, NC, USA Electronic address
J Immunol Methods 409:21-30. 2014..Overall, the CHAVI PBMC QA oversight program results highlight the relative importance of each of these stages to the ultimate goal of preserving specimen integrity from peripheral blood collection to long-term repository storage. ..
- Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral controlSusan A Sufka
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Infect Dis 187:1027-37. 2003..These findings suggest that discordant responses may be related to enhanced HIV-directed immune responses, diminished cellular activation, decreased viral replication capacity, and preservation of non-syncytium-inducing virus strains...
- Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adultsGeoffrey J Gorse
Department of Veterans Affairs Medical Center and Saint Louis University, St Louis, MO 63104, United States
Vaccine 26:215-23. 2008..Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic...
- A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regionsMatthew E Harris
Walter Reed Army Institute of Research, Washington, D C, USA
AIDS Res Hum Retroviruses 19:1125-33. 2003..Although immunological responses must be considered, from a phylogenetic perspective, there is no compelling support for use of Ethiopian subtype C sequences, compared to other subtype C, as vaccine prototype strains...
- Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infectionMichael R Betts
Laboratory of Immunology, Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 102:4512-7. 2005..These data suggest that control of HIV by vaccine-elicited HIV-specific T cell responses may be difficult, even when the T cell response has those characteristics predicted to provide optimal protection...
- Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trialsJosephine H Cox
U S Military HIV Research Program, Rockville, MD 20850, USA
AIDS Res Hum Retroviruses 21:68-81. 2005..This study highlights the need for better standardization of protocols and reagents to obtain reliable and reproducible data that may support immunogenicity studies, vaccine regulatory submissions, and licensure...
- Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected EthiopiansJeffrey R Currier
The U S Military HIV Research Program, Rockville, Maryland 20850, USA
AIDS Res Hum Retroviruses 21:239-45. 2005..Efforts to optimize the cross-reactivity of vaccine-induced CD8 T cells may need to focus on the relative immunogenicity of minor sequence variation...
- High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjectsPaul A Goepfert
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
J Infect Dis 192:1249-59. 2005..0) TCID50 (60 participants) than when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants)...
- Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell
Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
J Acquir Immune Defic Syndr 44:203-12. 2007..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy...
- Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV developmentMichael R Betts
University of Pennsylvania, Department of Microbiology, 522E Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
Expert Rev Vaccines 5:505-16. 2006..Furthermore, potential protective characteristics will be proposed that may ultimately be required for an effective vaccine designed to stimulate cellular immunity against HIV-1...
- Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul A Goepfert
University of Alabama at Birmingham, 908 20th Street South, CCB 328, Birmingham, AL 35294, USA
Vaccine 25:510-8. 2007..Use of the recombinant proteins NefTat and gp120(W61D) formulated with the AS02A adjuvant system was previously shown to protect against AIDS in a rhesus macaque SHIV animal model system...
- Standardization and validation issues of the ELISPOT assaySylvia Janetzki
ZellNet Consulting Inc, Fort Lee, NJ, USA
Methods Mol Biol 302:51-86. 2005..This chapter will give the experienced scientists as well as newcomers to the field an overview over the major standardization issues for each step of the protocol. Guidelines are given on how to validate the ELISPOT performance...
- Measurement of cytokine release at the single cell level using the ELISPOT assayJosephine H Cox
U S Military HIV Research Program, Henry M Jackson Foundation for the Advancement of Military Medicine, 13 Taft Court, Rockville, MD 20850, USA
Methods 38:274-82. 2006..The history, applications, validation process, and future challenges of the ELISPOT assay are discussed in this chapter...
- Poly-functional analyses of vaccine-induced T cell responsesGuido Ferrari; Fiscal Year: 2010..Overall, these findings will shed new insights on the importance and fate of vaccine-induced T cell responses in controlling HIV-infection. ..